Angiotensin-(1-7) reduces proteinuria and diminishes structural damage in renal tissue of stroke-prone spontaneously hypertensive rats

American Journal of Physiology - Renal Physiology

Volumn 300, Issue 1, 2011, Pages

  Giani, Jorge F ^a   Muñoz, Marina C ^a   Pons, Romina A ^a   Cao, Gabriel ^b   Toblli, Jorge E ^b   Turyn, Daniel ^a   Dominici, Fernando P ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b HOSPITAL ALEMÁN   (Argentina)

Author keywords

Albuminuria; Nephrin; NF B; Renin angiotensin system; TNF

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN (1 7); ANGIOTENSIN II; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; NEPHRIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; KIDNEY FIBROSIS; KIDNEY PARENCHYMA; MALE; NONHUMAN; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RAT; RENAL PROTECTION; SODIUM BLOOD LEVEL; SPONTANEOUSLY HYPERTENSIVE RAT; STROKE;

EID: 78651293193     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00278.2010     Document Type: Article

References (57)

1. Al-Maghrebi M, Benter IF, Diz DI. Endogenous angiotensin-(1-7) reduces cardiac ischemia-induced dysfunction in diabetic hypertensive rats. Pharmacol Res 59: 263-268, 2009.
2. Amazonas RB, Sanitax Rde A, Kawachi H, de Faria JB. Prevention of hypertension with or without renin-angiotensin system inhibition precludes nephrin loss in the early stage of experimental diabetes mellitus. Nephron Physiol 107: p57-p64, 2007.
3. Benter IF, Diz DI, Ferrario CM. Cardiovascular actions of angiotensin(1-7). Peptides 14: 679-684, 1993.
4. Benter IF, Yousif MH, Anim JT, Cojocel C, Diz DI. Angiotensin-(1-7) prevents development of severe hypertension and end-organ damage in spontaneously hypertensive rats treated with L-NAME. Am J Physiol Heart Circ Physiol 290: H684-H691, 2006.
5. Benter IF, Yousif MH, Cojocel C, Al-Maghrebi M, Diz DI. Angiotensin-(1-7) prevents diabetes-induced cardiovascular dysfunction. Am J Physiol Heart Circ Physiol 292: H666-H672, 2007.
6. Benter IF, Yousif MH, Dhaunsi GS, Kaur J, Chappell MC, Diz DI. Angiotensin-(1-7) prevents activation of NADPH oxidase and renal vascular dysfunction in diabetic hypertensive rats. Am J Nephrol 28: 25-33, 2008. (Pubitemid 350126490)
7. Benzing T. Signaling at the slit diaphragm. J Am Soc Nephrol 15: 1382-1391, 2004.
8. Blanco S, Bonet J, Lopez D, Casas I, Romero R. ACE inhibitors improve nephrin expression in Zucker rats with glomerulosclerosis. Kidney Int Suppl 93: S10-S14, 2005. (Pubitemid 40019208)
9. Chappell MC. Emerging evidence for a functional angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS receptor axis: more than regulation of blood pressure? Hypertension 50: 596-599, 2007.
10. Chatziantoniou C, Dussaule JC. Insights into the mechanisms of renal fibrosis: is it possible to achieve regression? Am J Physiol Renal Physiol 289: F227-F234, 2005.
11. Choi BS, Yang HJ, Ahn KO, Lim SW, Kim SH, Kim JY, Li C, Kim YS, Kim J, Bang BK, Yang CW. Renoprotective effects of rosiglitazone in stroke-prone spontaneously hypertensive rats. Kidney Blood Press Res 30: 212-223, 2007.
12. Clark MA, Diz DI, Tallant EA. Angiotensin-(1-7) downregulates the angiotensin II type 1 receptor in vascular smooth muscle cells. Hypertension 37: 1141-1146, 2001.
13. Clark MA, Tallant EA, Tommasi E, Bosch S, Diz DI. Angiotensin- (1-7) reduces renal angiotensin II receptors through a cyclooxygenase-dependent mechanism. J Cardiovasc Pharmacol 41: 276-283, 2003.
14. Deelman L, Sharma K. Mechanisms of kidney fibrosis and the role of antifibrotic therapies. Curr Opin Nephrol Hypertens 18: 85-90, 2009.
15. Dilauro M, Burns KD. Angiotensin-(1-7) and its effects in the kidney. Scientific World J 9: 522-535, 2009.
16. Dupont AG, Brouwers S. Brain angiotensin peptides regulate sympathetic tone and blood pressure. J Hypertens 28: 1599-1610, 2010.
17. Elmarakby AA, Quigley JE, Pollock DM, Imig JD. Tumor necrosis factor alpha blockade increases renal Cyp2c23 expression and slows the progression of renal damage in salt-sensitive hypertension. Hypertension 47: 557-562, 2006.
18. Esteban V, Heringer-Walther S, Sterner-Kock A, de Bruin R, van den Engel S, Wang Y, Mezzano S, Egido J, Schultheiss HP, Ruiz-Ortega M, Walther T. Angiotensin-(1-7) and the g protein-coupled receptor MAS are key players in renal inflammation. PLoS One 4: e5406, 2009.
19. Ferrario CM, Trask AJ, Jessup JA. Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. Am J Physiol Heart Circ Physiol 289: H2281-H2290, 2005.
20. Gagliardini E, Corna D, Zoja C, Sangalli F, Carrara F, Rossi M, Conti S, Rottoli D, Longaretti L, Remuzzi A, Remuzzi G, Benigni A. Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes. Am J Physiol Renal Physiol 297: F1448-F1456, 2009.
21. Gava E, Samad-Zadeh A, Zimpelmann J, Bahramifarid N, Kitten GT, Santos RA, Touyz RM, Burns KD. Angiotensin-(1-7) activates a tyrosine phosphatase and inhibits glucose-induced signalling in proximal tubular cells. Nephrol Dial Transplant 24: 1766-1773, 2009.
22. Geraldes P, King GL. Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res 106: 1319-1331, 2010.
23. Giani JF, Munoz MC, Mayer MA, Veiras LC, Arranz C, Taira CA, Turyn D, Toblli JE, Dominici FP. Angiotensin-(1-7) improves cardiac remodeling and inhibits growth-promoting pathways in the heart of fructose- fed rats. Am J Physiol Heart Circ Physiol 298: H1003-H1013, 2010.
24. Grobe JL, Mecca AP, Lingis M, Shenoy V, Bolton TA, Machado JM, Speth RC, Raizada MK, Katovich MJ. Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7). Am J Physiol Heart Circ Physiol 292: H736-H742, 2007.
25. Grobe JL, Mecca AP, Mao H, Katovich MJ. Chronic angiotensin-(1-7) prevents cardiac fibrosis in DOCA-salt model of hypertension. Am J Physiol Heart Circ Physiol 290: H2417-H2423, 2006.
26. Gruden G, Perin PC, Camussi G. Insight on the pathogenesis of diabetic nephropathy from the study of podocyte and mesangial cell biology. Curr Diabetes Rev 1: 27-40, 2005.
27. Hasegawa G, Nakano K, Sawada M, Uno K, Shibayama Y, Ienaga K, Kondo M. Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. Kidney Int 40: 1007-1012, 1991.
28. Hilgers KF, Mann JF. Role of angiotensin II in glomerular injury: lessons from experimental and clinical studies. Kidney Blood Press Res 19: 254-262, 1996.
29. Hruby ZW, Shirota K, Jothy S, Lowry RP. Antiserum against tumor necrosis factor-alpha and a protease inhibitor reduce immune glomerular injury. Kidney Int 40: 43-51, 1991.
30. Iusuf D, Henning RH, van Gilst WH, Roks AJ. Angiotensin-(1-7): pharmacological properties and pharmacotherapeutic perspectives. Eur J Pharmacol 585: 303-312, 2008.
31. Ji H, Menini S, Zheng W, Pesce C, Wu X, Sandberg K. Role of angiotensin-converting enzyme 2 and angiotensin(1-7) in 17beta-oestradiol regulation of renal pathology in renal wrap hypertension in rats. Exp Physiol 93: 648-657, 2008.
32. Jia J, Ding G, Zhu J, Chen C, Liang W, Franki N, Singhal PC. Angiotensin II infusion induces nephrin expression changes and podocyte apoptosis. Am J Nephrol 28: 500-507, 2008.
33. Lee J, Malvin RL, Jokelainen PT. Blood pressure and acidic renin forms in stroke-prone hypertensive rats. Am J Physiol Renal Fluid Electrolyte Physiol 257: F275-F279, 1989.
34. Little MA, Bhangal G, Smyth CL, Nakada MT, Cook HT, Nourshargh S, Pusey CD. Therapeutic effect of anti-TNF-alpha antibodies in an experimental model of anti-neutrophil cytoplasm antibody-associated systemic vasculitis. J Am Soc Nephrol 17: 160-169, 2006.
35. Loot AE, Roks AJ, Henning RH, Tio RA, Suurmeijer AJ, Boomsma F, van Gilst WH. Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation 105: 1548-1550, 2002.
36. Lubel JS, Herath CB, Tchongue J, Grace J, Jia Z, Spencer K, Casley D, Crowley P, Sievert W, Burrell LM, Angus PW. Angiotensin-(1-7), an alternative metabolite of the renin-angiotensin system, is upregulated in human liver disease and has antifibrotic activity in the bile duct-ligated rat. Clin Sci (Lond) 117: 375-386, 2009.
37. Mendes AC, Ferreira AJ, Pinheiro SV, Santos RA. Chronic infusion of angiotensin-(1-7) reduces heart angiotensin II levels in rats. Regul Pept 125: 29-34, 2005.
38. Mercure C, Yogi A, Callera GE, Aranha AB, Bader M, Ferreira AJ, Santos RA, Walther T, Touyz RM, Reudelhuber TL. Angiotensin(1-7) blunts hypertensive cardiac remodeling by a direct effect on the heart. Circ Res 103: 1319-1326, 2008.
39. Miceli I, Burt D, Tarabra E, Camussi G, Perin PC, Gruden G. Stretch reduces nephrin expression via an angiotensin II-AT1-dependent mechanism in human podocytes: effect of rosiglitazone. Am J Physiol Renal Physiol 298: F381-F390, 2010.
40. Navarro JF, Mora-Fernandez C. The role of TNF-alpha in diabetic nephropathy: pathogenic and therapeutic implications. Cytokine Growth Factor Rev 17: 441-450, 2006.
41. Oda H, Keane WF. Recent advances in statins and the kidney. Kidney Int Suppl 71: S2-S5, 1999.
42. Palmer BF. Proteinuria as a therapeutic target in patients with chronic kidney disease. Am J Nephrol 27: 287-293, 2007.
43. Pinheiro SV, Ferreira AJ, Kitten GT, da Silveira KD, da Silva DA, Santos SH, Gava E, Castro CH, Magalhaes JA, da Mota RK, Botelho-Santos GA, Bader M, Alenina N, Santos RA, Simoes e Silva AC. Genetic deletion of the angiotensin-(1-7) receptor Mas leads to glomerular hyperfiltration and microalbuminuria. Kidney Int 75: 1184-1193, 2009.
44. Putaala H, Soininen R, Kilpelainen P, Wartiovaara J, Tryggvason K. The murine nephrin gene is specifically expressed in kidney, brain and pancreas: inactivation of the gene leads to massive proteinuria and neo-natal death. Hum Mol Genet 10: 1-8, 2001.
45. Roson MI, Cavallero S, Della Penna S, Cao G, Gorzalczany S, Pandolfo M, Kuprewicz A, Canessa O, Toblli JE, Fernandez BE. Acute sodium overload produces renal tubulointerstitial inflammation in normal rats. Kidney Int 70: 1439-1446, 2006.
46. Santos RA, Ferreira AJ, Pinheiro SV, Sampaio WO, Touyz R, Campagnole-Santos MJ. Angiotensin-(1-7) and its receptor as a potential targets for new cardiovascular drugs. Expert Opin Investig Drugs 14: 1019-1031, 2005.
47. Santos RA, Ferreira AJ, Simoes ESAC. Recent advances in the angiotensin- converting enzyme 2-angiotensin(1-7)-Mas axis. Exp Physiol 93: 519-527, 2008.
48. Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, Heringer-Walther S, Pinheiro SV, Lopes MT, Bader M, Mendes EP, Lemos VS, Campagnole-Santos MJ, Schultheiss HP, Speth R, Walther T. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 100: 8258-8263, 2003.
49. Shankland SJ. The podocyte's response to injury: role in proteinuria and glomerulosclerosis. Kidney Int 69: 2131-2147, 2006.
50. Shao Y, He M, Zhou L, Yao T, Huang Y, Lu LM. Chronic angiotensin (1-7) injection accelerates STZ-induced diabetic renal injury. Acta Pharmacol Sin 29: 829-837, 2008.
51. Singh T, Singh K, Sharma PL. Ameliorative potential of angiotensin1- 7/Mas receptor axis in streptozotocin-induced diabetic nephropathy in rats. Methods Find Exp Clin Pharmacol 32: 19-25, 2010.
52. Toblli JE, DeRosa G, Cao G, Piorno P, Pagano P. ACE inhibitor and angiotensin type I receptor antagonist in combination reduce renal damage in obese Zucker rats. Kidney Int 65: 2343-2359, 2004.
53. Toblli JE, Ferrini MG, Cao G, Vernet D, Angerosa M, Gonzalez- Cadavid NF. Antifibrotic effects of pioglitazone on the kidney in a rat model of type 2 diabetes mellitus. Nephrol Dial Transplant 24: 2384-2391, 2009.
54. Wang X, Desai K, Juurlink BH, de Champlain J, Wu L. Gender-related differences in advanced glycation endproducts, oxidative stress markers and nitric oxide synthases in rats. Kidney Int 69: 281-287, 2006.
55. Whaley-Connell A, Habibi J, Nistala R, Cooper SA, Karuparthi PR, Hayden MR, Rehmer N, DeMarco VG, Andresen BT, Wei Y, Ferrario C, Sowers JR. Attenuation of NADPH oxidase activation and glomerular filtration barrier remodeling with statin treatment. Hypertension 51: 474-480, 2008. (Pubitemid 351156435)
56. Wysocki J, Ye M, Rodriguez E, Gonzalez-Pacheco FR, Barrios C, Evora K, Schuster M, Loibner H, Brosnihan KB, Ferrario CM, Penninger JM, Batlle D. Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension. Hypertension 55: 90-98, 2010.
57. Zhang J, Noble NA, Border WA, Huang Y. Infusion of angiotensin- (1-7) reduces glomerulosclerosis through counteracting angiotensin II in experimental glomerulonephritis. Am J Physiol Renal Physiol 298: F579-F588, 2010.